Core-Biomarker Development Laboratory
Core-Biomarker Development Laboratory
批准号:
10696075
负责人:
Paul Christopher Boutros
金额:
$38.45万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-02 至 2027-08-31
关键词:
AdoptionAgeAlgorithmsAmericanAutopsyBRCA2 geneBehaviorBenchmarkingBiochemicalBiological AssayBiological MarkersBiopsyCancer EtiologyCessation of lifeClassificationClinicalClinical ManagementDNA RepairDataData AnalysesData SetDefectDetectionDiagnosisDiseaseDistantEarly Detection Research NetworkEarly DiagnosisEarly identificationEcosystemExhibitsFosteringGene ExpressionGeneticGerm-Line MutationIncidenceIndolentInstitutionLaboratoriesLesionLifeLiquid substanceLocal TherapyMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of prostateMedical Care CostsMicroRNAsModernizationMolecularMolecular ProfilingMonitorMorbidity - disease rateNeoplasm MetastasisNewly DiagnosedNomogramsOutcomePathogenicityPathologicPatientsPerformancePopulationProstateProstatic NeoplasmsProteinsProteomicsProtocols documentationPublishingQuality of lifeRadiology SpecialtyResearch PersonnelRiskSiteSkin CancerStratificationTalentsTissuesTumor TissueUnited StatesUrineVariantVirginiaaging populationbiomarker developmentbiomarker panelbiomarker validationcancer diagnosiscandidate markercohortcostdiagnostic biomarkerdisorder riskefficacy testinggene repairgenetic testingimprovedinnovationlaboratory developmentlifetime riskmale healthmenmutantnew growthnovelpatient subsetspredictive markerprematureprotein biomarkersproteogenomicsrisk stratificationserum PSAstandard of caresynergismtooltumorurinaryvalidation studiesvariant of unknown significance
中文摘要
项目总结
英文摘要
Project Summary
The critical challenge in the clinical management of newly-diagnosed localized prostate cancer remains
distinguishing indolent from aggressive and life-threatening cancers. Biomarkers are urgently needed to
identify those patients who harbor aggressive disease and will derive benefit from definitive treatment. We
therefore, propose to apply complimentary proteogenomic-based discovery approaches to identify and then
validate molecular features in prostate proximal fluids and tumor tissues that will be utilized in accurate early
detection of aggressive forms of prostate cancer and improve disease risk stratification. The intended use of
these biomarkers will be the early identification of men at risk for grade progression and improved risk-
stratification for them.
We have three biomarker development laboratory aims: 1) Validate our existing urine-based biomarkers for
grade progression in a ProBE-compliant study selected from our own cohorts and the EDRN GU upgrading
study. 2) Develop and validate urine and tissue-based biomarkers for the risk-stratification of MRI “invisible”
high-grade lesions. 3) Develop and validate biomarkers to sub-stratify risk associated with deleterious
germline BRCA2 variants.
Our biomarker reference laboratory will develop and validate targeted clinically robust assays for multi-protein
biomarkers panels. We will also develop decision algorithms that are cross-referenced for statistical rigor and
benchmarked for optimal clinical performance. In addition to these BCC activities, we will develop robust
PRM-MS assays and statistically rigorous decision tools for other EDRN BCCs and CVCs.
Taken together, our EDRN biomarker characterization center will be a core part of the the EDRN ecosystem.
We will continue to actively participate in trans-Network activities, and to share patient cohorts, protocols,
datasets and analysis approaches and expertise. We will supplement these activities by focusing on
promoting the growth of new and diverse talent in biomarker development through fostering junior investigator
involvement across the full spectrum of biomarker development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Germline Determinants of Prostate Cancer Evolution
-
批准号:10587968
-
项目类别:
-
资助金额:$62.89万
-
财政年份:2023
-
负责人:Paul Christopher Boutros
-
依托单位:
Tool Core- Boutros
-
批准号:10473401
-
项目类别:
-
资助金额:$135.92万
-
财政年份:2022
-
负责人:Paul Christopher Boutros
-
依托单位:
Virginia-UCLA-Toronto Biomarker Characterization Center
-
批准号:10696069
-
项目类别:
-
资助金额:$82.73万
-
财政年份:2022
-
负责人:Paul Christopher Boutros
-
依托单位:
Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer:
-
批准号:10705201
-
项目类别:
-
资助金额:$67.97万
-
财政年份:2022
-
负责人:Paul Christopher Boutros
-
依托单位:
Tool Core- Boutros
-
批准号:10655489
-
项目类别:
-
资助金额:$133.39万
-
财政年份:2022
-
负责人:Paul Christopher Boutros
-
依托单位:
The Evolution of Sarcoma Drug Sensitivity through Time and Space
-
批准号:10202513
-
项目类别:
-
资助金额:$49.69万
-
财政年份:2020
-
负责人:Paul Christopher Boutros
-
依托单位:
The Evolution of Sarcoma Drug Sensitivity through Time and Space
-
批准号:10434822
-
项目类别:
-
资助金额:$48.7万
-
财政年份:2020
-
负责人:Paul Christopher Boutros
-
依托单位:
The Evolution of Sarcoma Drug Sensitivity through Time and Space
-
批准号:10778672
-
项目类别:
-
资助金额:$33.48万
-
财政年份:2020
-
负责人:Paul Christopher Boutros
-
依托单位:
Signaling Drivers of Sarcoma Drug Resistance
-
批准号:10437547
-
项目类别:
-
资助金额:$33.48万
-
财政年份:2020
-
负责人:Paul Christopher Boutros
-
依托单位:
The Evolution of Sarcoma Drug Sensitivity through Time and Space
-
批准号:10646502
-
项目类别:
-
资助金额:$48.7万
-
财政年份:2020
-
负责人:Paul Christopher Boutros
-
依托单位:
The Evolution of Sarcoma Drug Sensitivity through Time and Space
-
批准号:10053260
-
项目类别:
-
资助金额:$45.62万
-
财政年份:2020
-
负责人:Paul Christopher Boutros
-
依托单位:
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer
-
批准号:9768391
-
项目类别:
-
资助金额:$42.01万
-
财政年份:2016
-
负责人:Paul Christopher Boutros
-
依托单位:
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer
-
批准号:10261032
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2016
-
负责人:Paul Christopher Boutros
-
依托单位:
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer
-
批准号:9353339
-
项目类别:
-
资助金额:$43.05万
-
财政年份:2016
-
负责人:Paul Christopher Boutros
-
依托单位:
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer
-
批准号:10004588
-
项目类别:
-
资助金额:$43.31万
-
财政年份:2016
-
负责人:Paul Christopher Boutros
-
依托单位:
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer
-
批准号:9277912
-
项目类别:
-
资助金额:$45.42万
-
财政年份:2016
-
负责人:Paul Christopher Boutros
-
依托单位:
Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer
-
批准号:10463890
-
项目类别:
-
资助金额:$12.76万
-
财政年份:2016
-
负责人:Paul Christopher Boutros
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: